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KIDNEY DISEASE IN PRIMARY ANTIPHOSPHOLIPID 
ANTIBODY SYNDROME 
 
ABSTRACT: 
 
Antiphospholipid syndrome (APS) is an autoimmune disease defined by the 
presence of arterial or venous thrombotic events and/or pregnancy morbidity in 
patients who test positive for antiphospholipid antibodies. APS can be isolated 
(primary APS) or associated with other autoimmune diseases. The kidney is a 
major target organ in APS and renal thrombosis can occur at any level within the 
vasculature of the kidney (renal arteries, intrarenal vasculature and renal veins). 
Histological findings vary widely, including ischaemic glomeruli and thrombotic 
lesions without glomerular or arterial immune deposits on immunofluorescence. 
Renal involvement in patients with definite APS is treated with long-term 
anticoagulants as warfarin but new treatments are being tried. The aim of this 
article is to review the links between primary APS and kidney disease. 
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INTRODUCTION: 
 
Antiphospholipid syndrome (APS) is a pro-thrombotic acquired autoimmune 
disease, characterized principally by vascular thrombosis (arterial and/or venous), 
pregnancy morbidity and the presence of antiphospholipid antibodies (aPL). These 
heterogeneous antibodies bind serum phospholipid-binding plasma proteins 
(mainly β2 glycoprotein-I, prothrombin, protein C, protein S, annexin V, annexin II, 
and oxidized low-density lipoprotein), phospholipid–protein complexes, and 
anionic phospholipids. The aPL tested routinely are the IgG and IgM anticardiolipin 
antibodies (aCL) detected by enzyme-linked immunosorbent assay (ELISA) and 
the lupus anticoagulant (LA), detected by clotting tests. Many laboratories now 
also test for IgG and IgM anti-β2 glycoprotein-I antibodies (by ELISA)  
 
APS can be primary or associated with other conditions, notably systemic lupus 
erythematosus (SLE). It may affect any organ and/or vessel. Renal involvement can 
be present in patients with either primary or SLE-associated APS. 
Renal involvement can be a serious problem for patients with APS. However, this 
complication has been poorly recognized and little studied. It can be present in 
either type of APS. In the most recent consensus criteria of APS [1,2] the term 
antiphospholipid-associated nephropathy (APLN) was suggested to describe the 
entity of aPL in association with renal vasculopathy. 
The true prevalence of APLN is unknown (ranging from 6 to 25% of patients with 
APS). An accompanying thrombocytopenia may limit the possibility of doing a 
renal biopsy. Furthermore, a recent study by Jordan and coworkers [3] identified 
the LA, presence of thrombotic microangiopathy (TMA) on renal biopsy, age 
>40years, and elevated serum creatinine (>400 γmoles/liter) as independent risk 
factors in a lupus cohort for increased risk of bleeding and major bleeding 
complications. These factors were significantly more common in those with 
coexisting APS and/or aPL. Severe renal histopathological lesions may be found in 
the absence of significant renal clinical abnormalities [4]. 
MATERIAL AND METHODS: 
A search was performed using a computer-assisted search engine.  Some terms 
used were: primary APS and anti-cardiolipin antibodies (aCL), anti-phospholipid-
associated nephropathy and APS, APS and renal vascular thrombosis, primary APS 
and treatment, primary APS nephropathy treatment, rituximab and APS, in the 
literature published until 2015.  
We performed a electronic search, piloted in PubMed and Embase. We 
supplemented electronic searches by checking references cited in published 
papers and in the articles extracted from the electronic searches. Unpublished 
studies were not searched.  
 
The following limits were applied: (a) written in English, Spanish or French; and 
(b) performed in humans. 
 
Studies were screened for inclusion in different phases: (a) duplicated articles 
were deleted; (b) we first screened by title and then by abstract. When a title 
seemed relevant, the abstract was reviewed for eligibility; if any doubt remained, 
the full text of the article was retrieved and discussed (Figure 1) 
 
After the selection, a total of 114 articles were selected. To facilitate the analysis, 
articles were classified according to the following categories: pathophysiology, 
renal artery lesions, renal vein thrombosis, APS nephropathy and treatment. 
 
PATHOPHYSIOLOGY 
A ‘two hit’ model of thrombosis in APS has been hypothesized in which a ‘first hit’ 
creates a pro-thrombotic state followed by a ‘second hit’, possibly inflammatory, 
that perturbs the endothelium and initiates thrombosis [5]. 
The pathophysiologic mechanisms that contribute to the prothrombotic phenotype 
(first hit) include aPL-mediated activation of monocytes, endothelial cells and/or 
platelets, and/or inhibition of natural anticoagulant and fibrinolytic systems by 
aPL [6]. 
The various factors potentially involved in the pathogenesis of the prothrombotic 
phenotype are shown in Figure 2. 
 
 
 
 ANTIPHOSPHOLIPID ANTIBODIES 
aPL are directed principally against phospholipid binding proteins, likely to be the 
main factor in the pathogenesis of APS, by binding to the surface of endothelial 
cells, monocytes and platelets. 
The loss of immune tolerance is thought to be responsible for the origin of 
pathogenic aPL, which appears to be predominantly antigen driven. Bacterial and 
viral infections have been implicated in the development of aPL and shown to 
induce pathogenic antibodies against b2GPI. aPL develop in mice immunized with 
a cytomegalovirus-derived peptide, and a recent study demonstrated that protein 
H of Streptococcus pyogenes can bind b2GPI and expose neoepitopes that induce 
production of anti-b2GPI antibodies [7,8]. 
It is probable that at least part of the injury observed in renal biopsies is related to 
the pathogenic action of aPL, which may be linked to prolonged immunological 
damage mediated by anti-DNA/nucleosome antibodies [9]. 
APLN is particularly associated with triple anti-phospholipid antibody positivity 
[10]. Gerhadsson and coworkers found that APLN was associated with aCL, but a 
strong trend between APLN and anti-β2GP1 or LA was also detected. However, in 
other studies [11], focussing on glomerular microthrombi, a strong association 
with LA and anti-β2GP1, but not with aCL was noted. Alternatively, it has been 
proposed that both LA and aCL are associated with an increased risk of vascular 
thrombosis [12,13], while other reports have verified this relationship only with 
LA [14-16].  
Finally, a study of 51 patients [17], suggested that the presence of aCL and/or 
glomerular thrombi predicts a worse renal outcome, as patients with aPL-
positivity had significantly more crescents, sclerosis, and glomerular necrosis. 
These patients tend to develop hypertension and raised serum creatinine levels, in 
addition to other manifestations of APS, especially arterial thromboses, during the 
course of the disease. 
It has been further demonstrated that aPL-associated vascular lesions have an 
ominous effect on long-term renal function, arterial hypertension, and absence of 
response to immunosuppressive agents [9,18,19]. 
In contrast, others have shown no significant differences between patients with or 
without aPL-associated nephropathy in complete or partial remission, non-
response to treatment or at end-stage renal disease [20]. 
The divergent aPL associations previously reported are likely to be due to 
methodological issues, as different assays for aPL and LA detection have been 
used, and cut-off values have varied between studies. 
 CELLULAR ACTIVATION 
aPL have been reported to bind to, and activate vascular endothelial cells, 
monocytes, and platelets in a b2GPI-dependent manner [21-24]. 
Endothelial cells, through the expression of anticoagulant proteins and the 
elaboration of antithrombotic substances such as prostacyclin, glycosaminoglycans 
and nitric oxide, play an important role in maintaining blood fluidity. Endothelial 
cell activation via aPL – b2GPI interactions leads to loss of these anticoagulant 
properties with transformation to a pro-adhesive, procoagulant phenotype, 
characterized by increased expression of adhesion molecules and tissue factor, 
enhanced secretion of pro-inflammatory cytokines and chemokines, and the 
release of procoagulant and proinflammatory microparticles [25]. 
The vascular endothelium of proliferating intrarenal vessels, from patients with 
APLN, showed indications of the mechanistic target of rapamycin complex 
(mTORC) pathway activation. This phenomenon was also found in the vessels of 
autopsy specimens from patients with the sinister catasthrophic APS. Patients with 
APLN who required transplantation and were receiving sirolimus, had no 
recurrence of vascular lesions and had decreased vascular proliferation on biopsy, 
compared to patients with aPL not on the drug. These results suggest that mTORC 
pathway is involved in the vascular lesions associated with the antiphospholipid 
syndrome [26]. 
In contrast, Rauch et al. [27] showed TLR4 involvement in inducing a break in 
immune tolerance and production of aPL. Dysregulation of other TLRs including 
TLR7, TLR8, and TLR9 may also contribute to the development of aPL [28]. 
Hydroxychloroquine inhibits TLR7 and is associated with reduced persistence of 
aPL in patients with SLE [29]. 
 
 COMPLEMENT ACTIVATION 
Recent studies have shown that complement activation (induced by or coordinated 
with aPL), and the complement-induced tissue factor activation, may play a 
significant role in renal tissue injury [30]. 
Activation of the complement system is implicated in the development of 
thrombosis and fetal loss in APS [31]. Activated complement fragments bind to and 
activate cells through, the C5b-9 membrane attack complex or, through the C5a-
receptor-mediated effects. aPL, which activate complement may generate the 
potent inflammatory mediator C5a, which recruits neutrophils and monocytes, and 
leads to the tissue factor exposure by endothelial cells and neutrophils [32].  
Recently, several case reports have documented the successful use of eculizumab 
(humanized anti-C5a monoclonal antibody) in patients with complicating renal 
transplantation APS [33]. 
  HLA 
A link between certain HLA haplotypes and ALPN has been described. Thus, 
Gerhadsson and co-workers found a significantly higher frequency of HLA-
DRB1*13 as concluded that a genetic predisposition may contribute to APLN [10]. 
The activation of mTORC pathway in endothelial cells during humoral rejection by 
anti-HLA antibodies (particularly anti-HLA class I antibodies) of primary APS. 
However, a recent study has shown that anti-HLA antibodies did not account for 
mTORC activation in microvascular endothelial cells; therefore, more studies are 
necessary to correlate this association [26].  
 
CLINICAL MANIFESTATIONS 
APS nephropathy is clinically characterized by a vascular nephropathy syndrome 
associated with hypertension, acute or chronic renal failure and proteinuria [34]. 
Proteinuria is generally mild (range between 0.5–3.0 g per day), but is occasionally 
nephrotic (>3.5 g per day) [9,35,36].  
The presence of newly developed hypertension in a patient with positive aPL, in 
combination with proteinuria, haematuria and/or renal insufficiency should raise 
a suspicion of APLN, and kidney biopsy should be performed. When APLN lesions 
are detected in kidney biopsies, other causes associated with similar histological 
lesions should be excluded including malignant hypertension, thrombotic 
thrombocytopenic purpura or haemolytic uremic syndrome, scleroderma, 
cyclosporine use or human immunodeficiency virus (HIV) infection [30]. 
When APLN is a result of renal artery thrombosis, different clinical feature may be 
observed, most commonly, pain in the renal area or renal failure associated with 
severe hypertension or worsening of known systemic hypertension. Renal 
ultrasonography, abdominal CT, renal angiography, renal scintigraphy and 
gadolinium-enhanced magnetic resonance angiography have proved useful for 
diagnostic and prognostic purposes. Magnetic resonance angiography and renal 
ultrasonography with colour Doppler sonography are comparable methods for the 
detection of renal artery stenosis with lumen diameter narrowing ≥60%. However, 
renal ultrasonography with colour Doppler sonography is preferred as a screening 
method which helps to exclude renal vein thrombosis [37-39].  
Nephrotic syndrome is uncommon among patients with primary APS, being more 
frequent in patients with secondary APS concomitant with SLE [40]. In the large 
patient cohort described by Tektonidou and co-workers, patients with APLN 
developed hypertension, raised serum creatinine levels and histological 
progression of lesions, all of which are associated with poor renal. However, the 
frequency of renal insufficiency did not differ between patients with or without 
APLN during 7-years follow-up [9]. 
Usually APLN progresses slowly, only rarely leading to end-stage renal failure [41]. 
Primary APS is not usually considered in children with unexplained acute renal 
failure, nor is it considered to be cause of end-stage renal disease (ESRD), in adults 
or children [42]. However, there is a case report about a 53-year-old lady with end-
stage renal failure in primary APS [43,44]. 
 
MACRO-ANATOMIC AND MICROSCOPIC FINDINGS 
There are numerous classifications for renal manifestations of APLN based on their 
location [45]. They can be divided in 3 main groups, each having its own 
pathogenic, clinical and diagnostic characteristics: (Figure 3) 
 Renal artery lesions, secondary to thrombosis, stenosis or occlusion of the 
main artery (uni- or bilateral) 
 Intrarenal vascular lesions (require biopsy confirmation) 
 Renal vein thrombosis 
 
 RENAL ARTERTY 
Renal artery involvement is a relatively common manifestation in patients with 
APS. In 2003, magnetic resonance angiography (MRA) was performed in 88 APS 
patients with poor control of their blood pressure and compared them to two 
control groups, one of young patients with hypertension and the other of potential 
kidney donors. A total of 20 patients (28%) affected by APS had lesions in the renal 
artery, significantly higher than in the other groups [46,47]. 
Although early studies focused on cases of APS associated with SLE, there is an 
increasing number of reports that focus on the presence of renal artery 
impairment in patients with primary APS [48]. 
In 1992, Rossi et al. [49] reported two cases of renovascular hypertension with 
renal artery stenosis, and suggested a possible relationship between renal 
stenosis, thrombosis, aPL and fibromuscular dysplasia. This idea was supported by 
Mandreodi and colleagues [50]. Other studies described many cases of renal artery 
occlusion as a manifestation of APS, and related them to severe hypertension as 
the prime clinical manifestation [49,51-60]. 
In general, two patterns of renal artery stenotic (RAS) lesions, with some unique 
features, have been documented in APS patients. The more frequent pattern is 
characterized by smooth, well-delineated, and often noncritical stenosis, distal to 
the ostium of the renal artery. Less frequently a pattern similar to atherosclerotic 
lesions, proximal and occasionally involving the aorta has been reported [47, 61, 
62]. 
Thus renal artery occlusion may be due to two different mechanisms; the renal 
disease may be related to an in situ stenosis or thrombosis, or be due to an embolic 
event (such as a heart valve vegetation). However, some reports were not able to 
find a definitive cause for the renal infarction [52]. 
Occasionally hypertension may not be present in early stages of the disease, which 
may complicate the differential diagnosis and lead to delayed diagnosis  [63]. 
Therefore, in all cases of unknown cause of renal artery stenosis, a diagnosis of 
APS should be considered. In addition to laboratory tests, renal scintigraphy and 
selective renal angiography facilitates the confirmation of the diagnosis and the 
extent of the lesions [45].  
 INTRARENAL VASCULAR LESIONS  
 
o Glomerular thrombosis 
Unlike lupus nephritis, where there are studies suggesting that patients with 
proliferative glomerulonephritis have a capillary thrombosis rate up to 50% and 
whose presence implies a stronger prognostic marker [64], in primary APS, this 
finding is not specific. Amigo, et al described vascular lesions (both in arterioles 
and glomerular capillaries) often presenting with mesangiolysis, mesangial 
interposition, electronlucent subendothelial material, and ischemic obsolescence 
of glomeruli. Renal biopsies also showed arterial luminal narrowing due to medial 
hypertrophy, amorphous mucoid deposits within the intima, thrombosis, and 
general fibrosis [35,65] 
Nochy and colleagues studied kidney biopsy specimens from 16 patients with APS, 
in which, a combination of glomerular basement membrane wrinkling and 
reduplication were seen ultra-structurally [66]. 
Other histopathologic findings have been described, but these are not specific for 
APLN [45]. (Figure 4) 
 
 
 
o Intra-renal vascular lesions 
Several reviews considered the involvement of the renal microvasculature to be 
the most frequent biopsy finding [67-69].  
Gerhandsson et al. described 236 renal biopsies from 112 SLE patients concluding 
that, in comparison to patients with pure lupus nephritis, the presence of APLN 
was associated with intimal changes, inflammatory infiltrates, interstitial fibrosis 
and tubular atrophy [10]. 
The most commonly reported and characteristic intrarenal vascular lesion, in 
patients with APS [35,45,70-73] is TMA, characterized by the presence of 
distinctive microscopic and ultrastructural changes [74].  
The most common clinical features of TMA include: hypertension, proteinuria, and 
renal impairment. Proteinuria is often mild but can be within nephrotic range 
[35,75]. 
Histologically, focal or diffuse microangiopathic changes, affecting the whole 
intrarenal vascular tree and the glomerular tufts, have been observed [35,66].  
TMA is characterized by the presence of fibrin thrombi in glomeruli and/or renal 
arterioles and an absence of immune complexes and inflammatory cells. It lacks an 
association with any specific histologic class of lupus nephritis [30]. Rarely, TMA 
can be associated to diffuse mesangial interposition with numerous double 
contours. By immunofluorescence (IF), the immunoglobulins are absent and the 
thrombi contain fibrin.  
Intrarenal TMA may be the first manifestation that leads to a diagnosis of primary 
APS [76]. It has been emphasized that APS should be considered in the differential 
diagnosis of systemic hypertension and, that APS-related TMA may cause isolated 
hypertension without significant renal impairment.  
Histologically, the morphological features of TMA are specific to a pathophysiology 
associated with thromboses, but they do not show any etiologic specificity. Other 
conditions including thrombotic thrombocytopenic purpura, haemolytic uremic 
syndrome, post-partum renal failure, pre-eclampsia/eclampsia, scleroderma, 
malignant arterial hypertension or drugs (cyclosporine, chemotherapy, 
contraceptives), can produce similar lesions. The morphologic lesions are 
insufficient to make an “etiologic diagnosis”, and require additional clinical and 
laboratory data, including aCL and LA determination, as well as exclusion of 
colibacillary infections, chronic hypertension, systemic sclerosis among others 
[45,77]. 
A recent study [78] found that the inclusion of renal vascular lesions in the 2003 
International Society of Nephrology/Renal Pathology Society (ISN/RPS) 
histological classification system of lupus nephritis, improves renal outcome 
prediction. TMA was associated with the poorest renal outcome among the other 
renal vascular lesions. 
Atherosclerosis, among the fibrous lesions, present in 75% of biopsies in some 
reports [35], is not specific. By contrast, fibrous intimal hyperplasia (FIH) 
(described in 75% of the specimens), arteriolar occlusions (68%) and focal cortical 
atrophy (FCA) (62%) are only seen infrequently in other vascular nephropathies, 
and are highly suggestive of APLN when they are observed in the same biopsy with 
interstitial fibrosis and foci of tubular atrophy with pseudothyroidization (75%) 
FIH of arterioles and interlobular arteries show a plexiform pattern of tortuous 
vessels with a cellular proliferation of actin-positive myofibroblastic cells in the 
intima, associated with an increased extracellular matrix. Most of these vessels 
have a reduced lumen obstructed by fibrous projections, cushions or organizing 
thrombi with recanalization [36]. 
FIH with organized thrombi was the second vascular lesion observed [79] in renal 
biopsies from a group of pregnant women with APS and LA. These lesions were 
also described by others in patients with primary APS, not only in intrarenal 
arteries, but also in other organs like: brain, lung, heart or skin [72,80-83]. 
The fibrotic vascular lesions of typical nephroangiosclerosis (NAS) are relatively 
acellular, with diffuse arteriosclerosis and exceptional FIH. Arteriosclerosis is 
more fibrous, often characterized by an atrophic media with, on occasions, an 
onion-skin arrangement of the intima of the blood vessels.  
Tubular atrophy with pseudothyroidization and interstitial fibrosis are frequently 
observed, but tend to be more diffusely distributed without the isolated 
subcapsular foci, typical of FCA. This appearance is likely to be because the lesions 
of typical NAS are more uniformly distributed than is the case for FCA in APLN. 
Furthermore, the organized thrombi, responsible for vascular occlusion in APLN, 
are absent in NAS [4]. 
Among the chronic pathological aspects, atherosclerosis is typically associated 
with intimal fibrous hyperplasia, thickening of arteries due to fibrosis, and 
proliferation of myofibroblastic cells; with the consequent lumen restriction and 
ischemia, which is common in APLN and rarely seen in other nephropathies 
[36,84]. 
Redundant and wrinkled segments of basal membrane accompanied by a duplicate 
straighter thin membrane adjacent to the endothelium have been reported as a 
pathognomonic feature of the syndrome. In addition, some authors suggest an 
association between minimal change nephropathy and focal segmental 
glomerulosclerosis, both as independent clinical-pathological presentations of 
APLN [39,74,85] 
Fakhouri and co-workers [86] reported some new aspects of the renal 
involvement in APS, in a study of 29 biopsies from patients with GN associated 
with APS in the absence of underlying autoimmune disorders. Twenty biopsies 
showed characteristic APLN features. However, predominant pathological 
features, distinct from vascular APS nephropathy, were noted in 9 biopsies, 
including: membranous nephropathy (MN) (3 cases), minimal change 
disease/focal segmental glomerulosclerosis (3 cases), mesangial C3 nephropathy 
(2 cases), and pauci-immune crescentic GN (1 case). 
Other cases of MN in association with APS have been reported [72,86-88],. 
Moreover, in a series reported by Quereda and colleagues, aPL were detected in 3 
out of 15 patients with MN (20%), 2 of whom fulfilled APS diagnostic criteria [89]. 
o Cortical renal ischemia 
Occlusion of small isolated parenchymatous renal vessels causes small foci of 
cortical necrosis. These are generally asymptomatic. However, if they are multiple 
or generalized they may lead to patchy or diffuse cortical necrosis as described in 
the catastrophic APS [90]. 
One of the first reported cases was a 27-year-old man with coronary occlusion, 
arterial hypertension, thrombophlebitis, atrial thrombus, and positive aPL. An 
abdominal CT scan revealed cortex hypodensity in both kidneys. Renal biopsy 
showed diffuse interstitial fibrosis, mononuclear infiltration, sclerotic and ischemic 
glomeruli with negative immunofluorescence studies. These findings suggest 
cortical sclerosis and atrophy as sequelae from old cortical necrosis [91]. 
Pérez et al. [83] reported a man with APS and multi-organ arterial and venous 
thrombosis, seemingly a catastrophic syndrome. This patient had a 2-cm renal 
cortical infarction and multiple petechiae in the renal cortex. At autopsy, an 
organizing interlobular vein thrombus plus microthrombi in the microvasculature 
of the medulla were found. This case illustrated medium- and small-vessel 
thrombosis affecting the intra- and extra-renal vasculature. 
The FCA, located in the subcapsular renal cortex, associated with dense interstitial 
fibrosis leading to tissue retraction and kidney contour depression, giving it a scar-
like appearance with sharp borders surrounded by areas of normal parenchyma, 
which is considered to be very typical of APLN [24,84]. 
The fibrotic lesions of FIH and FCA are observed in surgical nephrectomies 
performed to reduce hypertension in cases of unilateral renal artery stenosis. In 
these surgical samples, zones of subcapsular depression representing foci of FCA 
with ischemic and cystic changes can be found with vascular lesions of FIH, often 
quite proliferative, with zones of tubular pseudothyroidization.  
The great similarities of these lesions with those of APLN suggest they have the 
same pathophysiology. This could be the consequence of parenchymal ischemia 
and activation of the renin-angiotensin system. By contrast, the vascular occlusions 
by thrombi with recanalization are not seen in these kidneys downstream nor are 
arterial stenosis [4]. 
Amigo and García-Torres suggested that cortical renal ischemia is a well-defined 
clinicopathologic entity in patients with APS. The lesion may leave a variable 
impairment of renal function [45]. 
The additional presentation of renal cortical ischemia was described by Leaker et 
al. [75] This is an insidious, slowly progressive nephropathy that in the long term, 
leads to renal failure. Clinically, patients have arterial hypertension, mild 
proteinuria, and a slowly progressive renal failure. 
o Renal vein thrombosis 
Surprisingly, renal vein thrombosis is a rare complication of primary APS, whereas 
peripheral vein thrombosis is a common feature. By contrast, renal vein 
thrombosis is a well-known complication of membranous nephropathy with 
nephrotic syndrome, either idiopathic or associated with SLE [92-96]. 
Isolated cases of renal vein thrombosis have been reported in patients with PAPS, 
including one case of bilateral renal vein thrombosis in the postpartum period 
[96]. 
TREATMENT 
Control of hypertension, associated with various other drugs (antiplatelet drugs, 
anticoagulants, steroids, or rarely plasma exchange) may lead to remarkable 
improvement in renal function [1,69,76,97,98]. 
Heparin anticoagulation, followed by long-term vitamin K antagonist 
anticoagulation is the mainstay of thrombotic APS therapy. However, a significant 
proportion of patients have recurrent thrombosis despite antithrombotic therapy 
[99]. Vitamin K antagonists are also problematic due to food or drug interactions, 
bleeding complications, and the need for frequent monitoring. Furthermore, aPL 
interact variably with different thromboplastin reagents, affecting the 
prothrombin time monitoring and international normalized ratio [100]. 
Sangle et al. reported the effect of anticoagulation on blood pressure (BP) control 
and renal function in hypertensive APS patients. 14 such APS patients with renal 
artery stenosis, who received oral anticoagulation for more than 1 year, were 
studied retrospectively. Patients were divided into 2 groups based on their 
International Normalized Ratio (INR) (<3.0 and ≥3.0). The results suggested that 
patients whose INR was maintained ≥3.0 did well, their BP was better controlled 
(BP was 120/80 mm Hg), renal function remained stable or improved, and renal 
artery stenosis was reversed in some patients. In contrast, patients with a median 
INR <3.0 had poorly controlled BP, a significant deterioration in mean serum 
creatinine values [101].  
Remondino and coworkers [102] described recanalization of bilateral RAS and BP 
normalization in a young hypertensive woman with APS. These findings support 
the idea that anticoagulation with maintained ≥3.0 INR, may have an important 
role in preventing the progression of these renal artery lesions. 
However, the role of anticoagulation therapy in the evolution of renal function is 
uncertain, due to the limited number of patients and follow‐up period in the 
majority of cases [30]. Even when full anticoagulation is administered following 
renal allografting, the risks of graft loss and systemic thrombosis were not 
completely eliminated [103]. 
Unfortunately, there are no available recommendations about the optimal 
anticoagulation regimen to be used during renal transplantation.  
The risk of systemic or renal vasculature thrombosis is high in aPL‐positive 
patients; However, the risk of graft failure due to major bleeding should be 
considered. In addition, the anticoagulation therapy efficacy in preventing 
thrombotic microangiopathy is uncertain [104,105]. 
The oral direct thrombin inhibitors (dabigatran) and direct factor Xa inhibitors 
(rivaroxaban and apixaban) overcome some of these disadvantages. They are 
prescribed at a fixed dose, do not need routine monitoring, and have few drug or 
food interactions. However, they are irreversible and there is limited experience in 
patients with APS. There are no data recommending their use in APS patients with 
APLN, though results of the RAPS (rivaroxaban in anti-phospholipid antibody 
syndrome) study comparing warfarin and rivaroxaban in PAS patients with history 
of venous thrombosis are expected shortly. 
 
Good control of systemic hypertension may be hard to achieve, but is vital to 
prevent  the progression to end-stage renal disease [43]. 
Biologic therapy 
Other therapeutic approaches have been attempted in refractory cases, including 
the use of intravenous Ig, plasmapheresis and rituximab [106,107].  
Rituximab has been shown to decrease the titres of aPL and, therefore, should 
decrease the thrombotic risk of patients with APS [108]. Thus, Ioannou and 
colleagues [109] reported a major fall in IgG anticardiolipin (aCL) antibody titres in 
seven SLE patients who had received treatment with rituximab and 
cyclophosphamide. Moreover, 8 out of 12 APS patients treated with rituximab due 
to recurrent thrombosis or refractory thrombocytopenia showed normalization or 
a reduction in aPL titres [110]. The Rituximab in AntiPhospholipid Syndrome 
(RITAPS) trial, a prospective, open-label, phase II trial of rituximab in primary APS 
patients, reported that rituximab is also effective in controlling some noncriteria 
manifestations of APS such as thrombocytopenia, haemolytic anaemia, skin ulcers, 
and nephropathy [111]. The authors suggested that improvement might be due to 
the blockade of B-cell effector functions independent of antibody production. 
Two APLN patients were included in the open‐label phase II trial of rituximab for 
non‐criteria manifestations of APS; one patient withdrew early due to an infusion 
reaction, and the other had a partial response to treatment with rituximab [112]. 
Given this evidence, rituximab is an attractive alternative in the treatment of 
APLN. Reducing the number of B cells, rituximab may decrease both the aPL 
titres and also the production of ferritin and cytokines such as tumor necrosis 
factor-alpha, interleukin (IL)-1, IL-2, and IL-6, that may be responsible for some 
of the clinical features of APS [112]. 
Abatacept, a CTLA4 blocker, and belimumab, a BAFF antagonist, are approved for 
the treatment of rheumatoid arthritis and SLE, respectively, but to our knowledge 
have not yet been used in patients with antiphospholipid syndrome.  
Complement inhibition with the C5a inhibitor eculizumab has been successfully 
used in isolated kidney post-transplant TMA cases [113]. Eculizumab carries a risk 
of infection with encapsulated organisms and patients should be immunized 
against meningococcus before starting treatment [114]. 
The therapeutic effects on the complement inhibition, tissue factor inhibition and 
anti-CD20, need to be investigated in prospective long-term studies. Further 
research on APS pathogenesis may identify new potential targets for its treatment. 
Multicenter, prospective studies are also needed for the validation of APLN 
histological criteria and the identification of histological, clinical and laboratory 
characteristics of this worse renal prognosis nephropathy. 
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 Figure 2.  Modified from Chaturvedi, Shruti, and Keith R. McCrae. Recent Advances in the 
Antiphospholipid Antibody Syndrome. Current Opinion in Hematology 2014; 21(5):371–79. 
 
 Figure 3. PAPS and renal disease. Modified from R. García-Torres, and MC. Amigo. Kidney Disease in 
Antiphospholipid Syndrome. Rheum Dis Clin North Am 2006; 32(3):509–22 and Uthman, Imad, and Munther Khamashta. 
Antiphospholipid Syndrome and the Kidneys. Seminars in Arthritis and Rheumatism 2006; 35(6): 360–67. 
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Figure 4. Glomerular affectation. Modified from R. García-Torres, and MC. Amigo. Kidney Disease in 
Antiphospholipid Syndrome. Rheum Dis Clin North Am 2006; 32(3):509–22. 
 
